Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR, in the U.S. in December 2025 CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals ...

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Cancer Immunotherapy, LYMPHIR, launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which $18 million was via private placement and ...